SCHEMBL3598189

SCHEMBL3598189

Cc1nc2ccccc2n1CC(=O)NCCN(C)C1CCCCC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
HTT P42858 3/20 0.55
LMNA P02545 2/20 0.55
PTAFR P25105 2/20 0.54
GSK3B P49841 5/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
MAPT P10636 1/20 0.46
HIF1A Q16665 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608185 0.89 HSD17B10 (0.51) TSHRHTTLMNAPTAFRALDH1A1
SCHEMBL3589935 0.89 LMNA (0.50) TSHRHTTLMNAPTAFRALDH1A1
SCHEMBL3587770 0.88 ALDH1A1 (0.48) TSHRHTTPTAFRALDH1A1KDM4E
SCHEMBL3595687 0.87 ALDH1A1 (0.49) TSHRHTTPTAFRALDH1A1KDM4E
SCHEMBL3596888 0.87 HTT (0.63) TSHRHTTLMNAALDH1A1KDM4E
SCHEMBL3610555 0.86 KDM4E (0.69) TSHRHTTALDH1A1KDM4EHPGD
SCHEMBL3591240 0.84 TSHR (0.41) TSHRHTTLMNAPTAFRALDH1A1
SCHEMBL3599800 0.83 HPGD (0.47) TSHRHTTALDH1A1HPGDGAA
SCHEMBL3598193 0.81 LMNA (0.57) TSHRHTTLMNAPTAFRGSK3B
SCHEMBL3600246 0.80 GAA (0.55) HTTALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 TSHR 1277/4885HTT 1553/4885LMNA 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.